MASTER-2
MRD-Guided Sequential Therapy For Deep Response in Newly Diagnosed Multiple Myeloma - MASTER-2 Trial
Arms / Cohorts
Experimental, Arm A:Daratumumab + Bortezomib + Lenalidomide + Dexamethasone (MRD - Patients)
Accepting patients
Active Comparator, Arm B:Daratumumab + Lenalidomide (MRD - Patients)
Accepting patients
Experimental, Arm C:Teclistamab + Daratumumab (MRD + Patients)
Accepting patients
Active Comparator, Arm D:Daratumumab + Lenalidomide (MRD + Patients)
Accepting patients
Arm M:Daratumumab + Lenalidomide + Bortezomib + Dexamethasone
Accepting patients
Real People. Real Support.
Need help connecting with this clinical trial? We're here to help!
Print a patient-friendly report to share with your patient.
We can help answer any questions and connect you (or your patient) with the study team.
Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.